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Abstract
Many neurodegenerative diseases are increasing in prevalence and cannot be prevented or cured. If they shared common
pathogenic mechanisms, treatments targeting such mechanisms might be of benefit in multiple conditions. The tau protein
has been implicated in the pathogenesis of diverse neurodegenerative disorders, including Alzheimer’s disease (AD) and
Parkinson’s disease (PD). Tau reduction prevents cognitive deficits, behavioral abnormalities and other pathological changes
in multiple AD mouse models. Here we examined whether tau reduction also prevents motor deficits and pathological
alterations in two mouse models of PD, generated by unilateral striatal injection of 6-hydroxydopamine (6-OHDA) or
transgene-mediated neuronal expression of human wildtype a-synuclein. Both models were evaluated on Tau+/+, Tau+/– and
Tau–/– backgrounds in a variety of motor tests. Tau reduction did not prevent motor deficits caused by 6-OHDA and slightly
worsened one of them. Tau reduction also did not prevent 6-OHDA-induced loss of dopaminergic terminals in the striatum.
Similarly, tau reduction did not prevent motor deficits in a-synuclein transgenic mice. Our results suggest that tau has
distinct roles in the pathogeneses of AD and PD and that tau reduction may not be of benefit in the latter condition.
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Introduction
Neurodegenerative disorders are on the rise, most likely because
greater longevity is increasing the age of populations around the
world and age is a major risk factor for these conditions [1–3].
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the
most prevalent of these disorders and no treatments are available
to prevent, halt or reverse them. If these diseases had pathogenic
mechanisms in common, drugs might be developed to target these
mechanisms for the benefit of both patient groups. It is interesting
in this regard that AD and PD overlap clinically. A proportion of
patients show manifestations of both diseases [4–8], and first-
degree relatives of patients with early-onset AD are at increased
risk of developing PD [9]. The two diseases also overlap
pathologically. A substantial proportion of AD patients have Lewy
bodies in their brain, which are hallmarks of PD [10–12].
Conversely, a proportion of PD patients have amyloid plaques in
their brain, which are hallmarks of AD [13,14]. Both AD and non-
demented PD patients have hyperphosphorylated tau [15–18],
which aggregates in AD and in some cases of PD without
dementia [19–25]. In addition, specific variants of the human tau
(MAPT) gene appear to be genetic risk factors for PD [26–29].
Reduction of endogenous murine tau prevents cognitive deficits
and various pathological alterations in several transgenic mouse
models of AD [30–33]. Furthermore, neuronal overexpression of
human a-synuclein in transgenic mice causes phosphorylation and
aggregation of endogenous tau [18,34–36]. In light of these
findings and a recent report that tau reduction prevented dendritic
degeneration in a neuronal culture model of mutant LRRK2-
linked PD [37], we wondered whether tau reduction is also
beneficial in mouse models of PD.
Human PD is characterized, among other things, by motor
abnormalities such as slowed movements, rigidity, unstable
posture and abnormal gait [38]. Pathologically, PD is character-
ized by loss of dopaminergic neurons in the substantia nigra,
degeneration of their tyrosine hydroxylase (TH)-containing
projections into the striatum and aggregation of a-synuclein into
Lewy bodies [38].
Several of these abnormalities can be simulated in rodent
models through administration of neurotoxins that target dopa-
minergic neurons or through neuronal expression of transgenes
that encode relevant pathogenic proteins. Unilateral injection of 6-
hydroxydopamine (6-OHDA) into the striatum of wildtype mice
causes loss of TH-positive terminals in the striatum on the
ipsilateral side and motor deficits [39]. This model can be used to
address the question whether tau reduction protects dopaminergic
neurons in the substantia nigra against neurotoxins and whether
tau reduction can prevent motor deficits caused by dopaminergic
cell loss. Either of these effects could be beneficial in PD. In a
different PD-related model, neuronal expression of human wild-
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type a-synuclein (hSYN) causes motor deficits in transgenic mice
[40–42]. This model can be used to address the question whether
tau is necessary for a-synuclein-induced pathogenesis. Here, we
evaluated both of these models on Tau+/+, Tau+/– and Tau–/–
backgrounds to determine whether tau reduction diminishes the
severity of their motor deficits and pathological alterations.
Materials and Methods
Mouse Models
Sex-matched groups of 2.6–5.8-month-old Tau+/+, Tau+/–, and
Tau–/– mice [43] on a C57BL/6 background were used for striatal
injections of 6-OHDA or vehicle. Heterozygous transgenic mice
expressing hSYN directed by the Thy1 promoter on a mixed
C57BL/6 and DBA/2 background [44] were crossed with Tau–/–
C57BL/6 mice and their F1 offspring were intercrossed to
generate mice with or without hSYN on the Tau+/+, Tau+/–, or
Tau–/– backgrounds. Only males were used for behavioral testing
at 3.0–4.5 months of age. At the end of experiments, mice were
deeply anesthetized with Avertin and killed by transcardial
perfusion with saline. One or both hemibrains were fixed in 4%
paraformaldehyde (from 32% solution, Electron Microscopy
Services, PA) in phosphate buffer (pH 7.4). For hSYN mice, one
hemibrain was frozen on dry ice. All experiments were approved
by the Committee on Animal Research of the University of
California, San Francisco (Approval Number AN085899-01A).
6-OHDA Injection
Mice were anesthetized, placed in a stereotaxic device and
injected with either 2 ml containing 4 mg of 6-OHDA (Sigma, MO)
in a solution of 2% L-ascorbic acid (Sigma, MO) in saline or the
ascorbic acid-saline solution alone (vehicle). A single injection was
performed in the striatum at the following coordinates relative to
bregma: anterior-posterior = +0.4, medial-lateral =+2.0, dorsal-
ventral =23.3. Injections were made at a rate of 0.5 ml/min with
a 10-ml syringe (Hamilton Company USA, NV). Behavioral testing
for acute effects of 6-OHDA began on the third day after injection
and was completed within seven days. Behavioral testing to assess
recovery began 24 days after the injection and was also completed
within seven days.
Open Field
A Flex-Field/Open Field Photobeam Activity System (San
Diego Instruments, CA) was used to assess spontaneous move-
ment. Mice were acclimated to the testing room for one hour
before testing. Each mouse was placed in the center of a clear
plastic chamber (41641630 cm) with two 16616 photobeam
arrays and allowed to explore for 15 min. Movements were
recorded through the number of beam breaks and rearing was
determined by beam breaks on the higher of the two arrays. The
chamber was cleaned with 70% ethanol between mice. In our
hands, hSYN mice at this age had no difference in total
movements or rearing in the open field compared to nontrans-
genic mice, thus the tau-modulated hSYN cohort was not tested in
the open field.
Rota Rod
Mice were acclimated to the testing room for one hour before
each session. Five mice were placed on the Rota Rod (Med
Associates Inc, VT) for simultaneous testing and the computer
recorded photobeam interruption when mice fell off the rotating
rod. Photobeams were interrupted by the tester if the mouse held
onto the rod without walking for three full rotations. Each mouse
was given three trials with a maximum time on the Rota Rod of
300 seconds and with a 10-min rest between trials. The mice were
first trained on the Rota Rod at a constant speed of 16 rpm. The
next day they were trained on the Rota Rod in the morning at an
accelerating speed of 4 rpm to 40 rpm over 300 s. In the
afternoon, mice were tested on the Rota Rod at the same
acceleration of 4 rpm to 40 rpm over 300 s and the average
latency to fall off the Rota Rod was analyzed.
Pole Test
The pole test was modified from previously reported protocols
[41]. The pole consisted of a thin wooden dowel and a cross-
shaped wooden base placed in a clean cage. Rubber bands were
wrapped around the dowel at intervals of approximately 1.5 inches
to increase traction. Mice were acclimated to the testing room for
one hour before each session. Mice were placed at the top of the
pole facing downwards and latency to descend the pole was
measured. Trials were excluded if the mouse jumped or slid down
the pole rather than climbed down. On the first day, each mouse
was trained with two trials. On the second day, each mouse was
given five trials and the lowest latency to descend the pole was
analyzed.
Gait Analysis
Gait analysis was done using the DigiGait software and
treadmill (Mouse Specifics, Inc., MA). Mice were acclimated to
the testing room for one hour before testing. Mice were placed on
the treadmill and the belt speed was set at a constant pace of
15 cm/s. Mice were allowed to walk for several seconds until a
regular gait pattern was observed; 4–5 seconds of gait video were
then recorded. Mice were excluded if a regular gait pattern could
not be recorded. Variable thresholds were set on the DigiGait
software to allow the computer to identify and analyze the mouse
paws from the recorded video clips. After the software analyzed
each video, the data was manually curated to ensure that the
analysis corresponded to actual paw placement. Any data that
consistently misidentified paw placement on the belt was excluded
from analysis.
Hind Limb Clasp
The hind limb clasp test was performed as described [45]. Mice
were acclimated to the testing room for one hour before testing.
Each mouse was lifted by the tail and slowly lowered toward a
surface for 10 s. The hind limbs were observed and each mouse
was given a score for each trial. A score of 0 indicated that the
hind limbs were extended for .50% of the trial period, a score of
1 indicated that one hind limb was retracted for .50% of the trial
period, a score of 2 indicated that both hind limbs were partially
retracted for .50% of the trial period, and a score of 3 indicated
that both hind limbs were fully retracted and touching the
abdomen for .50% of the trial period. Each mouse was tested
three times and the scores were analyzed as described in the
statistics section.
Balance Beam
The balance beam consisted of two platforms connected by a
removable plastic beam leading to an opaque box on top of one
platform. Mice were acclimated to the testing room for one hour
before testing. On the first day, mice were trained on a thick,
round beam by placing them first a few inches from the box and
leading them into the box, and then by placing them halfway
across the beam and leading them into the box, if leading was
required. The mice were then trained three times across the whole
length of the beam with approximately 10 min between each trial.
Tau-Independent Deficits in PD Models
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On the second day, mice were again trained three times on the
thick beam. On the third day, the thick beam was replaced with a
thin, square beam and the mice were tested three times. The
average latency to cross the thin beam and the average number of
times a foot slipped while mice crossed the beam during the testing
sessions was analyzed. A trial was excluded from analysis if the
mouse dragged its hind limbs across the beam for .50% of the
distance. Acutely after 6-OHDA injection mice could not
complete the balance beam test.
Immunohistochemistry
Fixed hemibrains were sectioned by microtome (Leica Micro-
systems Inc., IL) into 30-mm sections, which were then stored at
220uC in a solution containing 30% glycerol (Fisher, PA), 30%
ethylene glycol (Fisher, PA) and 40% phosphate-buffered saline
(from 106 stock solution, Mediatech, Inc., VA) until immuno-
staining. Rabbit anti-TH (1:2000 ab152, Abcam, MA) was used as
the primary antibody. Primary antibody binding was detected with
biotinylated donkey anti-rabbit (1:500, Jackson Immunoresearch,
PA), followed by avidin-biotin complex (Vector, CA). To
determine the extent of the loss of striatal dopaminergic
projections after 6-OHDA injection, the percent area occupied
by TH immunoreactivity was determined with the percent area
function of BIOQUANT (BIOQUANT Image Analysis Corpo-
ration, TN), in which the entire striatum was outlined by a
variable region of interest and the percent area showing a staining
signal above a set threshold was measured. Percent area on the
injected side of the striatum was normalized to the percent area on
the contralateral uninjected side. In hSYN transgenic mice, striatal
TH immunoreactivity was quantitated by densitometry.
Statistical Analysis
Investigators were blinded with respect to the genotype and
treatment of mice during testing. Most measures were analyzed by
two-way ANOVA and a Bonferroni post-hoc test with selected
comparisons (Prizm, GraphPad Software, CA). Data points
greater than two standard deviations from the mean for their
group were excluded from analysis. In data where the variance
between groups was severely unequal (Bartlett’s test p,0.0001),
the data was transformed by either a square-root, cube-root or log
transformation to normalize variance between the groups.
Whichever transformation best normalized variance was then
analyzed by two-way ANOVA and a Bonferroni post-hoc test. All
transformed data displayed equal variance across groups except
rearing after the four-week recovery (Bartlett’s test p = 0.03). Two
data sets were analyzed differently. The TH quantification was
analyzed by one-way t-tests compared to 100% with a Benjamini-
Hochberg p-value correction and by one-way ANOVA with a
Bonferroni post hoc test to compare treated groups to each other.
To assess genotype effects and genotype interaction in the hind
limb clasp test, the raw score data was analyzed by probit
regression with random effects taken into account (Stata,
StataCorp LP, TX). Comparisons between individual genotype
groups were made by Welch’s t-test of the average hind limb clasp
scores for each mouse with a Benjamini-Hochberg p-value
correction for multiple comparisons.
Figure 1. Tau Reduction Does Not Prevent Motor Deficits Induced by Acute Striatal 6-OHDA Injection. Mice (n=9–12 per treatment
and genotype) received a unilateral striatal injection of 6-OHDA or vehicle at 2.6–5.8 months of age and were tested behaviorally
beginning 3 days later. A) Total movements in the open field were reduced by 6-OHDA treatment and by tau reduction (p,0.0001 for treatment
effect, p=0.01 for genotype effect, and p= 0.054 for interaction by two-way ANOVA). B) Rearing in the open field was reduced by 6-OHDA regardless
of tau levels (p,0.0001 for treatment effect, p= 0.09 for genotype effect, and p= 0.15 for interaction by two-way ANOVA after cube-root
transformation). C) Latency to fall off an accelerating Rota Rod was reduced by 6-OHDA but not by tau reduction (p,0.0001 for treatment effect,
p= 0.40 for genotype effect, and p=0.22 for interaction by two-way ANOVA after cube-root transformation). D) Latency to descend in the pole test
was increased by 6-OHDA and by tau reduction (p,0.0001 for treatment effect, p=0.05 for genotype effect, and p= 0.11 for interaction by two-way
ANOVA). *p,0.05, **p,0.01, ***p,0.0001 vs. vehicle-treated mice of same Tau genotype or as indicated by bracket (Bonferroni test with selected
comparisons of vehicle vs. 6-OHDA treatment within each genotype, and Tau+/+ vs. Tau–/– for each treatment). Error bars represent SEM.
doi:10.1371/journal.pone.0029257.g001
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Results
Tau Ablation Does Not Prevent Abnormalities Caused by
6-OHDA and Worsens Some of Them
To evaluate the effects of tau reduction acutely and after
recovery from 6-OHDA injection, Tau+/+, Tau+/– and Tau–/– mice
received unilateral injections of 6-OHDA into the striatum and
were examined for motor abnormalities in the open field, Rota
Rod and pole tests beginning 3 days (Fig. 1) and 24 days (Fig. S1)
thereafter. Acutely, 6-OHDA injected mice of all three genotypes
showed reduced movements and rearing in the open field
(Fig. 1A,B) and reduced latency to fall off the accelerating Rota
Rod (Fig. 1C). 6-OHDA increased the latency to descend the pole
in the pole test only in mice with reduced tau levels, but not in
wildtype mice (Fig. 1D). In vehicle injected mice, tau ablation
reduced activity in the open field (Fig. 1A) but did not significantly
affect performance in the other tests (Fig. 1B–D).
After the recovery period, all groups of mice showed a similar
level of activity in the open field (Fig. S1A). Tau ablation also had
no effects on recovery of motor functions in the other tests at this
stage, with 6-OHDA injected Tau+/+ and Tau–/– mice showing no
significant differences in rearing, Rota Rod fall latency or pole
descent latency (Fig. S1B–D).
To assess the effect of 6-OHDA on striatal projections from
dopaminergic neurons in the substantia nigra, we immunostained
brain sections from the behaviorally tested mice for TH (Fig. 2A).
Vehicle treated mice showed no loss of TH staining (Fig. 2A,
quantification not shown). 6-OHDA treatment caused a loss of
striatal TH in all three genotypes, and there was a strong trend
towards increased TH losses in 6-OHDA injected mice with
reduced tau levels (Fig. 2B). Thus, tau ablation does not prevent,
and may partly enhance, acute motor and pathological deficits
induced by 6-OHDA injection.
Tau Reduction Does Not Prevent Motor Deficits in
Human Wildtype a-Synuclein Transgenic Mice
Mice with neuronal expression of hSYN directed by the Thy1
promoter (hSYN mice) were crossed onto the Tau+/+, Tau+/– or
Tau–/– background. Motor functions of the resulting offspring
were assessed at 3.0–4.5 months of age. Independent of Tau
genotype, hSYN expression caused abnormalities in fall latency in
the Rota Rod test (Fig. 3A), stride length (Fig. 3B), hind limb clasp
reflex (Fig. 3C), latency to cross a balance beam (Fig. 3D) and foot
slips on the balance beam (Fig. 3E). Tau reduction did not
significantly modulate these effects (Fig. 3A–E). In mice without
hSYN, tau ablation increased latency to cross and foot slips on the
balance beam (Fig. 3D and E), but had no significant effect on the
other measures.
To assess the effect of tau ablation on the pathology of SYN
mice, we examined striatal TH staining in the behaviorally tested
mice. Compared with wildtype mice, hSYN mice showed no
decreases in striatal TH staining on any of the Tau backgrounds
(data not shown), consistent with previous findings in hSYN/
Tau+/+ mice at this age [46].
Discussion
These findings demonstrate that tau reduction does not protect
mice against motor deficits and pathological alterations caused by
striatal injection of 6-OHDA or transgene-mediated neuronal
expression of hSYN. Thus, wildtype murine tau does not appear to
contribute causally to PD-like motor deficits and pathological
alterations in these models. In contrast, endogenous tau is required
for amyloid-b (Ab) peptides to impair neurons in primary cultures
[47–49] and in human amyloid precursor protein (hAPP)
transgenic mice [30,32,33]. It is also needed for apolipoprotein
E4, the most important genetic risk factor for AD, to cause
cognitive decline and neuronal loss in knockin mice [31].
However, tau reduction did not alter the age of disease onset or
mortality in a mouse model of amyotrophic lateral sclerosis [33],
providing further support for the conclusion that tau specifically
contributes to functional and pathological abnormalities in
experimental models of some neurodegenerative disorders but
not of others.
It is important to consider the limitations of the mouse models
used in this study and the extent to which one can extrapolate
from these models to human PD. Because the 6-OHDA model is
caused by an acute insult, it probably does not simulate the
etiology of sporadic PD, a notoriously chronic condition.
However, it is a robust model of dopaminergic cell loss and of
motor deficits resulting from deficient dopaminergic input to the
striatum, two cardinal features of PD. Our data suggest that
wildtype tau does not enable the neural network dysfunction that
underlies such motor deficits. This result was not predictable as tau
enables neuronal hypersynchrony in models of AD [33] and
neuronal hypersynchrony has also been implicated in the
pathophysiology of PD [50,51]. The differential effects of tau
reduction in models of AD versus PD suggest that tau plays distinct
roles in their pathogenic mechanisms. The hSYN mice used in this
study model a-synuclein-induced behavioral alterations and may
Figure 2. Tau Reduction Does Not Prevent Loss of TH after
Striatal Injection of 6-OHDA. Mice (n = 7-12 per treatment and
genotype) received a unilateral striatal injection of 6-OHDA or vehicle at
2.6–5.8 months of age and were analyzed by tyrosine hydroxylase
immunohistochemistry and light microscopy 50 days later. A)
Representative photomicrographs from a vehicle-injected wildtype
mouse and 6-OHDA injected mice of different Tau genotypes
demonstrating loss of TH immunoreactivity in the striatum. B) The
effect of 6-OHDA was quantitated by expressing the area of TH
immunostaining on the lesioned side as a percentage of that on the
unlesioned side of the brain. 6-OHDA caused loss of TH immunoreac-
tivity in the striatum and there was a trend toward greater losses in
groups with reduced tau levels. ***p,0.0001 vs. 100% (no loss of
dopaminergic projections) by one-sample t-test with a Benjamini-
Hochberg correction. One-way ANOVA between groups showed no
significant changes. Error bars represent SEM.
doi:10.1371/journal.pone.0029257.g002
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be relevant to the early pathogenesis of PD and other
synucleinopathies. However, they do not replicate PD-like
neurodegeneration in the substantia nigra at this age [52], possibly
due to low a-synuclein expression levels in this structure. Our
results indicate that tau does not enable or mediate early a-
synuclein-induced motor deficits in this model.
Notably, we cannot exclude a pathogenic role of tau in humans
with PD or other synucleinopathies or that tau reduction might be
of benefit in specific forms of PD, for example, those caused by
LRRK2 mutations [37]. It is therefore interesting to comment on
potential risks of tau reduction beyond lack of therapeutic benefit
in forms of PD simulated by the models examined in the current
study. Of all the functional outcome measures we evaluated in 6-
OHDA injected mice and untreated hSYN mice, tau reduction
significantly worsened only one: descent latency of 6-OHDA
injected mice in the pole test (Fig. 1D), suggesting that the risk of
enhancing PD-like alterations by tau reduction may be low. Tau
reduction also had rather subtle effects on pathological measures
in the PD models analyzed here. Although tau reduction appeared
to exacerbate the 6-OHDA-induced loss of TH immunoreactivity
in the striatum, this trend did not reach statistical significance.
Furthermore, tau reduction per se had relatively subtle effects in
only two of our behavioral tests in vehicle injected controls or
untreated mice lacking hSYN. In vehicle injected mice, tau
Figure 3. Tau Reduction Does Not Prevent Motor Deficits in hSYN Transgenic Mice. hSYN mice on different Tau backgrounds (n = 12–15
per group) were analyzed behaviorally at 3.0–4.5 months of age. A) Transgenic expression of hSYN impaired performance on an accelerating Rota
Rod, reducing fall latencies. Tau reduction was associated with non-significant trends towards improved fall latencies in mice with hSYN and towards
impaired fall latencies in mice without hSYN (p,0.0001 for hSYN effect, p=0.96 for Tau effect, and p=0.04 for genotype interaction by two-way
ANOVA). B) hSYN mice had shortened stride lengths regardless of Tau genotype (p,0.0001 for hSYN effect, p= 0.014 for Tau effect, and p= 0.97 for
interaction by two-way ANOVA). C) hSYN mice showed prominent increases in hind limb clasp reflex and tau reduction showed a non-significant
trend to worsen this abnormality (p,0.001 for hSYN effect, p=0.45 (Tau+/–) and p=0.91 (Tau–/–) for Tau effects, and p= 0.46 (Tau+/–) and p= 0.48
(Tau–/–) for hSYN interaction by probit regression). D, E) Transgenic expression of hSYN and tau reduction both increased (D) the latency to cross a
balance beam (p,0.0001 for hSYN effect, p= 0.07 for Tau effect, and p= 0.94 for interaction by two-way ANOVA) and (E) the number of foot slips
while crossing a balance beam (p,0.0001 for hSYN effect, p= 0.022 for Tau effect, and p=0.19 for interaction by two-way ANOVA after square root
transformation). Between 33–54% of mice in each hSYN group had to be excluded from balance beam analysis because they dragged their hind
limbs across the beam. *p,0.05, **p,0.01, ***p,0.0001 vs. mice without hSYN on the same Tau genotype or as indicated by bracket (Bonferroni test
(A, B, D, E) or Welch’s t-test with a Benjamini-Hochberg correction (C) for selected comparisons of + vs. – hSYN for each Tau genotype and Tau+/+ vs.
Tau–/– for each hSYN genotype). Error bars represent SEM.
doi:10.1371/journal.pone.0029257.g003
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reduction was associated with decreased total movements in the
open field acutely after the injection (Fig. 1A), but not after a three
week recovery period (Supp. Fig. 1A). In untreated mice lacking
hSYN, tau reduction impaired performance on the balance beam
(Fig. 3D, E). However, these impairments were much less severe
than those caused by hSYN expression (p = 0.009 for balance
beam latency and p,0.0001 for foot slips comparing Tau–/– with
hSYN/Tau+/+ mice by two-tailed t-test). Thus, tau reduction was
well tolerated overall and caused only minimal motor deficits.
Because tau reduction effectively prevented AD-like abnormal-
ities in hAPP transgenic mice but not PD-like deficits in the models
analyzed here, it is tempting to speculate that tau plays different
roles also in the human conditions and that tau reduction might be
beneficial in AD, but not in the most common forms of PD.
Additional studies are needed to further test these hypotheses and
to further explore the potential therapeutic value of this strategy in
different neurological conditions.
Supporting Information
Figure S1 Tau Reduction Does Not Alter Recovery of Motor
Function after 6-OHDA Injection. Mice (n = 7-12 per genotype
and treatment) received a unilateral striatal injection of 6-OHDA
or vehicle at 2.6–5.8 months of age and were tested behaviorally
beginning 24 days later. A) Total movements in the open field
were similar in all groups. B) Rearing in the open field was
reduced by 6-OHDA and this abnormality was improved by tau
ablation (p=0.003 for treatment effect, p=0.04 for genotype
effect, and p=0.44 for interaction by two-way ANOVA after log
transformation). C) Fall latency on the accelerated Rota Rod was
decreased by 6-OHDA treatment regardless of Tau genotype
(p,0.0001 for treatment effect, p=0.71 for genotype effect, and
p=0.15 for interaction). D) Latency to descend in the pole test was
increased by 6-OHDA mostly in Tau+/– mice (p,0.0001 for
treatment effect, p=0.04 for genotype effect, and p=0.09 for
interaction). *p,0.05, **p,0.01, ***p,0.0001 vs. vehicle-treated
mice of same Tau genotype or as indicated by bracket (Bonferroni
test with selected comparisons as in Fig. 1). Error bars represent
SEM.
(TIF)
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